Amazon adds generic prescription perk for Prime members

Amazon adds generic prescription perk for Prime members


Amazon launches RxPass; new prescription perk for U.S. Prime members

Amazon on Tuesday announced a new prescription perk for U.S. Prime members, hoping to boost subscriptions and attract users to its pharmacy service.

The add-on, called RxPass, will allow Prime members to get as many drugs as they need from a list of 50 generic medications to treat more than 80 common chronic conditions, such as high blood pressure, anxiety and diabetes. The service costs $5 a month per person, and delivery is free.

Amazon has pushed deeper into health care in recent years. The company launched its own online pharmacy in 2020, a service that was born out of its acquisition of PillPack in 2018. Amazon introduced, then shuttered, a telehealth service called Amazon Care, and announced in July it would acquire boutique primary care provider One Medical.

Amazon also offers a Prime prescription savings benefit, which offers a discount of up to 80% on generic medications and up to 40% on brand-name prescriptions.

Amazon is beefing up perks for its Prime subscription program as CEO Andy Jassy looks to cut costs elsewhere in the company. Amazon has eyed laying off about 18,000 employees, while it froze hiring in its corporate workforce and axed some projects. Still, Jassy has said Amazon intends to keep pursuing long-term opportunities, including health care.

The e-retailer faces competition in pharmacy from the likes of CVS, Walgreens and Walmart. Amazon hasn’t said how its online pharmacy offering has fared since its launch. An August report from Morgan Stanley found Amazon Pharmacy didn’t rank as a top perk for Prime members, based on a survey of users, according to Business Insider.

Amazon Pharmacy’s chief medical officer, Vin Gupta, said the company is aiming to deliver a pharmacy experience that is “fundamentally different” from how pharmacies have existed over the last several decades.

“This is still day one for us where we’re at our beginning stages here, but we recognize that change is needed,” Gupta said in an interview. “That’s what patients across the country are telling us, and that’s what Amazon is responding to.”

RxPass doesn’t offer insulin or specialty medications, and it’s not available for people on Medicaid or Medicare. Gupta declined to say whether Amazon will expand the list of medications offered through RxPass in the future.

Approximately 150 million people are on at least one of the medications included in the initial RxPass formulary, he said.

— CNBC’s Bertha Coombs contributed to this article.



Source

Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here
Health

Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here

Wall Street is optimistic that Olema Pharmaceutical could be developing the next major breakthrough breast cancer treatment. Earlier this month, the company announced promising clinical data for its lead candidate palazestrant, an oral medication that is being evaluated in several trials for estrogen receptor-positive, or ER+, breast cancer. Shares of the clinical-stage biopharmaceutical company are up […]

Read More
This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is ‘growing substantially’
Health

This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is ‘growing substantially’

It’s been a stellar few months for shares of San Francisco-based biotech company Rigel Pharmaceuticals, which has approved treatments for rheumatology and oncology — as well as potential new drugs in the pipeline. The stock has jumped about 50% in just the last three months, earning it a spot on CNBC’s list of top performing […]

Read More
We’re raising our Eli Lilly price target — what a difference a quarter makes
Health

We’re raising our Eli Lilly price target — what a difference a quarter makes

Eli Lilly shares jumped Thursday after the drugmaker posted a strong third quarter, driven by sales of its popular GLP-1 medications. The company also raised its full-year sales outlook for the second time in a row, inspiring confidence in the trajectory of the franchise. Revenue in the three months ended Sept. 30 jumped 54% year […]

Read More